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Dear Editor,
RRuxolitinib (RUX) is the first JAK1/JAK2 inhibitor
(JAKi) approved for the treatment of splenomegaly and
symptoms related to myelofibrosis (MF)1,2. By JAK1
inhibition, RUX reduces the production of several
inflammatory cytokine (IL-6, IL-1rα, MIP-1β, TNF-β, and
CRP), whereas myelosuppression is mainly exerted
through JAK2 inhibition. Despite considerable clinical
efficacy, some patients fail to obtain and/or maintain a
stable response or are intolerant to RUX3,4. Thus, ~40% of
patients discontinue RUX within 3 years of therapy5.
In the early phase I/II study of RUX in MF, most
patients experienced relapse of their symptoms and
worsening splenomegaly after RUX discontinuation1, and
life-threatening adverse events (AEs) occurred in 5 out of
47 patients, including respiratory distress, septic-like
shock and disseminated intravascular coagulation-like
syndrome. These events, attributed to an acute rebound of
cytokine storm, were defined as RUX discontinuation
syndrome (RDS), and careful tapering under close
physician supervision was suggested as a preventive
strategy6. Further cases of severe AEs attributed to RUX
discontinuation have been subsequently described,
despite a careful stepwise reduction of RUX7–9, also in the
setting of patients that received RUX as a bridge to
transplantation10,11 (Supplemental Table 1). RDS typically
presents within 3 weeks from RUX discontinuation,
apparently without relation with RUX dose, and seems to
improve after RUX reintroduction. However, these find-
ings were based on case reports or limited series of
patients, and available data are insufficient to estimate the
impact of RDS in routine clinical practice.
The current study aims to investigate in a real-world
context: (1) modalities of RUX discontinuation; (2) inci-
dence, timing, and severity of RDS; (3) outcome and risk
factors associated with RDS.
In 2016, a clinical network was established to collect
information about RUX therapy in MF12. This network
now includes 22 academic hematology centers where MF
patients are followed by hematologists with specific MPN-
driven practice.
A specific survey was conducted in all participating
Centers with the scope to obtain comprehensive infor-
mation regarding timing/modalities of RUX discontinua-
tion, and subsequent outcome. RDS included all new
symptoms that occurred within 21 days from RUX dis-
continuation and were interpreted by the treating
Hematologist as caused by RUX discontinuation. Based
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on the previous definition, RDS was graded as mild if
no intervention was required, moderate if symptoms
required medical interventions including RUX restarting,
steroids, oral analgesics, and severe if intravenous medi-
cations, hospital admissions, splenectomy, or delaying
of hematopoietic allogeneic transplantation (HCT) were
needed11.
At data cutoff date (1 May 2020), 700 RUX-treated MF
patients were included in the database. After a median
follow-up from RUX start of 36.1 months, 251 (35.9%)
patients discontinued RUX and were evaluable for RDS.
At the time of decision to stop RUX, 53% of these 251
patients were older than 70, 68.5% presented anemia and
45.8% had large splenomegaly (>10 cm below costal
margin, BCM); 27.5% of patients had a MPN-10 Total
Symptom Score > 20. Failure (lack/loss of response, or
leukemic transformation) was the main cause of RUX stop
(60.6%), whereas AEs (mainly hematological) and other
reasons caused RUX discontinuation in 28.6% and 10.8%
of patients, respectively. In most cases, AEs were con-
comitant to failure/suboptimal responses. Indeed, at the
time of RUX stop, 36.7% of patients presented a platelet
count below 100 × 109/l and 31.5% had transfusion-
dependent anemia. Also, in 7.6% of the patients, a grade
2–3 infectious event was recorded before RUX
discontinuation.
RUX daily dose (mg BID) was: 5, 10, 15, or 20 in 46.2,
23.1, 15.6, and 15.1% of patients. Notably, at the time of
RUX start, the dose of RUX was 5, 10, 15, or 20mg BID in
27.9, 17.2, 18.4, and 36.5% of patients. The concomitance
of AEs with a poor response to RUX most likely led to a
progressive RUX dose reduction in many patients; hence,
at the time of the final decision to discontinue the drug,
many patients were already taking low doses.
In 162 patients, RUX was abruptly discontinued. In the
remaining 89 patients (35.5%), RUX dose was gradually
decreased before discontinuation. Tapering was asso-
ciated with hydroxyurea and/or corticosteroids in 34
(38.2%) patients. RUX tapering pattern was very variable
among Centers and consisted of dose reductions of 5 or
10mg per day at variable intervals, ranging from a dose
reduction every 30 days to one every 3 days. The median
duration of tapering was 14 days (range 3–60). No asso-
ciation was found between tapering use and clinical/
laboratory parameters or RUX dose at the time of RUX
discontinuation. However, tapering use was consistent
within the single Centers, and was regularly performed in
only 4 Hematology Centers (Supplemental Fig. 1).
RDS occurred in 34 (13.5%) patients after a median time
of 7 days (range, 2–21) from RUX stop. The incidence
rate of RDS was 0.7 per 100 patient-days.
RDS was mild in 21 (61.8%) patients. Mild RDS con-
sisted in symptomatic spleen increase in 62% of the cases,
whereas 9.4% of patients experienced a flare in
constitutional symptoms (fever, weight loss, night sweats);
in six patients (28.6%), other MF-related symptoms
(fatigue, itching, bone pain, abdominal discomfort)
occurred. The median time from RUX stop to mild RDS
was 10 days (3–21). After RUX discontinuation, ten
patients (47.7%) did not receive further therapy because of
progression to blast phase and/or unfitness; eight patients
(38%) were treated with different therapies (including
demethylating agents, splenectomy, and HCT), whereas
three patients (14.3%) received a JAKi, after a median time
of 9 months.
A moderate RDS occurred in 10 out of 34 (29.4%)
patients, after a median time from RUX stop of 8.5 days
(range, 3–20) and comparable to mild RDS. Moderate
RDS was represented by symptomatic spleen enlargement
(seven patients), or constitutional symptoms appearance/
increase (three patients). RDS therapy consisted in corti-
costeroids (eight patients) or enrollment in a clinical trial
with a non-JAKi. Three patients received RUX rechal-
lenge after an average time of 2.6 years from first
discontinuation.
A total of three cases of severe RDS were observed and
consisted of: spleen rupture causing splenectomy (case 1);
fever, dyspnea, confusion, and dizziness requiring hospi-
talization (case 2); severe ARDS treated in intensive
care unit (case 3) (Supplemental Figure 2). Severe RDS
occurred within 48 h after RUX discontinuation and
the patient’s condition rapidly improved after RUX
rechallenge.
No fatal cases of RDS were observed.
In multivariable Cox regression analysis, only platelet
count <100 × 109/l (HR 2.98, 95%CI 1.29–6.90) and spleen
≥10 cm BCM (HR 2.03, 95%CI 1.01–4.17) at RUX stop
were significantly associated with higher probability of
RDS (Fig. 1a). Overall, 19 out of 251 patients (7.6%) re-
started RUX after drug discontinuation. RDS was sig-
nificantly associated with the need of RUX rechallenge,
with 8/34 (23.5%) RDS patients eventually resuming RUX
(p < 0.001) (Fig. 1b). Notably, the occurrence of RDS did
not significantly influence overall survival.
Overall, this study shows that symptoms and/or sple-
nomegaly significantly increase in ~15% of patients soon
after RUX stop, with sometimes considerable clinical
deterioration in already frail patients. This frequency is
consistent with the report by Shanavas et al.11, who found
that 10 out of 66 (15%) patients treated with RUX before
HCT developed RDS. RDS was mild to moderate in eight
cases, and severe in two cases, eventually leading to HCT
delay. In our cohort, the incidence of severe RDS
appeared to be lower (1%) than initially reported (11%)6.
Whether this difference is related to the smaller number
or to a more advanced disease of patients enrolled in
phase I–II study, compared with those treated with RUX
in subsequent years, remains to be defined. Indeed,
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compared with patients included in the phase I/II trial,
that were all at intermediate-2/high risk and mostly (92%)
affected by severe splenomegaly, this study included many
patients that started RUX while at intermediate-1 risk
(47.2%), with a lower incidence of baseline large spleno-
megaly (63.3%) or thrombocytopenia (15.4%). Also, owing
to its retrospective nature, an underestimation of RDS
cannot be fully ruled out in the present study. However,
both experiences highlight that re-expansion of MF after
RUX can be sudden and potentially life-threatening, and
that a rapid diagnosis of RDS is critical, as the reintro-
duction of RUX can quickly improve clinical status in
most cases.
Since RDS is an early event, any other therapy should be
started as close as possible to RUX discontinuation, as
already observed and indicated in the context of RUX as
bridge to HCT13. Importantly, the possible occurrence of
RDS may be anticipated in a substantial fraction of
patients that discontinue RUX during the screening phase
of clinical trials enrolling patients with failure or sub-
optimal response to RUX. In these cases, careful mon-
itoring, and disclosure of potential risk of RDS to the
patients are recommended.
This real-world experience also highlights that, despite
specific indications14, prevention strategies of RDS were
infrequent and inconsistent across different Centers, with
only a minority of patients gradually reducing the dose or
introducing prophylactic corticosteroids. This has prob-
ably prevented the detection of a correlation between
tapering and RDS reduction. Despite these limitations,
implementation and standardization of discontinuation
strategies should be pursued for a better RDS prevention
in the future.
Finally, we observed that the risk of RDS was sig-
nificantly higher in patients with a greater burden of the
disease at the time of discontinuation. Particularly, the
increased incidence of RDS in patients with large sple-
nomegaly may indicate that unexpectedly, in at least some
patients deemed refractory to RUX, the maintenance of
JAK2 inhibition has a non-negligible activity. In this
context, the re-use of a JAKi may be particularly reason-
able. The reintroduction of RUX has already shown to
achieve some clinical responses15. Possibly, second-
generation JAKi may have an even greater clinical rele-
vance in this setting.
In conclusion, these results confirm the need for a
careful surveillance of MF patients at the time of RUX
discontinuation. A quick switch to alternative treat-
ments, if clinically indicated, should be planned parti-
cularly for patients who stop RUX with large
splenomegaly. In the absence of available alternatives,
the occurrence of RDS may indicate a residual disease
control activity and identify a population that can still
benefit from JAK2i.
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Fig. 1 Risk factors at ruxolitinib discontinuation associated with
subsequent discontinuation syndrome (a) and probability of RUX
rechallenge according to RDS (b). a Risk factors were identified with
a Cox regression model. In order to use a parsimonious model owing
to the small number of events, only variables with p value < 0.05 in
univariate analysis were considered for multivariable analysis.
Moreover, collinearity amongst variables was detected by means of
Pearson correlation test. Ultimately only platelet count and spleen size
were considered in multivariable analysis and both remained
statistically significant. b Given that RDS is a time-dependent covariate,
the curves were obtained with the Simon-Makuch technique to take
the change in an individual’s covariate status over time into account.
One week from ruxolitinib stop, which is the median time from RUX
stop to RDS occurrence, was chosen as the landmark time point.
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